Results 181 to 190 of about 42,703 (308)

Impact of seropositivity and disease-modifying antirheumatic drugs on pulmonary tuberculosis risk in rheumatoid arthritis. [PDF]

ERJ Open Res
Choi H, Eun Y, Han K, Jung JH, Jung W, Kim H, Shin DW, Lee H.   +7 more
europepmc   +1 more source

RESEARCH: Effects of Long‐Term Disease‐Modifying Antirheumatic Drugs on Endothelial Function in Patients with Early Rheumatoid Arthritis [PDF]

, 2010
M. Turiel, L. Tomasoni, S. Sitia, Silvana Cicala, L. Gianturco, Cristian Ricci, Fabiola Atzeni, Vito De Gennaro Colonna, Mariangela Longhi, Piercarlo Sarzi‐Puttini   +9 more
openalex   +1 more source

Impact of Delay of Treatment With Disease-Modifying Antirheumatic Drugs in Psoriatic Arthritis: The CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. [PDF]

ACR Open Rheumatol
Mease PJ, Nowak M, Choi J, Lehman T, Sreih A, Ho K, Middaugh N, Ogdie A.   +7 more
europepmc   +1 more source

Impact of conflicting information on the use of antirheumatic drugs in pregnancy and breastfeeding: perspectives of healthcare providers from the global PRAISE survey. [PDF]

Ther Adv Musculoskelet Dis
Schreiber K, Graversgaard C, Parodis I, Agmon-Levin N, Aguilera S, Antovic A, Bertsias GK, Bini I, Bobirca A, Capela S, Cervera R, Costedoat-Chalumeau N, Dolhain R, Etomi O, Flint J, Fonseca JE, Fritsch-Stork R, Förger F, Giles I, Goulden B, Götestam Skorpen C, Gunnarsson I, Gupta L, Koksvik HS, Linde L, Lykke J, Meissner Y, Molto A, Moore L, Mosca M, Nelson-Piercy C, Perez-Garcia LF, Raio L, Rom AL, Rottenstreich A, Saleh M, Sciascia S, Strangfeld A, Svenungsson E, Tektonidou MG, Tincani A, Troldborg A, Vojinovic J, Voss A, Wallenius M, Zuniga-Serrano N, Andreoli L.   +46 more
europepmc   +1 more source

Initiation Patterns of Disease-Modifying Antirheumatic Drugs That Have Potential to Exacerbate Heart Failure. [PDF]

J Am Heart Assoc, 2023
Lee SB, D'Andrea E, Desai RJ.
europepmc   +1 more source

Canadian Rheumatology Association Recommendations for Pharmacological Management of Rheumatoid Arthritis with Traditional and Biologic Disease-modifying Antirheumatic Drugs [PDF]

, 2011
Vivian P. Bykerk, Pooneh Akhavan, Glen Hazlewood, Orit Schieir, Anne Dooley, Boulos Haraoui, Majed Khraishi, Sharon LeClercq, Jean Légaré, DIANE P. MOSHER, James Pencharz, Janet Pope, John Thomson, Carter Thorne, Michel Zummer, Claire Bombardier   +15 more
openalex   +1 more source

Risk of Serious Infections in Patients Treated With Biologic or Targeted-synthetic Disease Modifying Antirheumatic Drugs in Qatar. [PDF]

Immun Inflamm Dis
Sasi S, Hadi HA, Chaponda M, El Ajez R, Ataelmanan M, Khasawneh S, Saqallah H, Ali M, Abdulla N, Iqbal J, Omrani AS, Al Maslamani M, Al-Khal A.   +12 more
europepmc   +1 more source

Cost Effectiveness Analysis of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis. A Systematic Review Literature [PDF]

, 2011
Maurizio Benucci, Gianantonio Saviola, Mariangela Manfredi, Piercarlo Sarzi‐Puttini, Fabiola Atzeni   +4 more
openalex   +1 more source

Cardiovascular Outcomes of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis: A Review of the Current Evidence. [PDF]

Cureus
Sunkara P, Garikipati NA, Nimmagadda R, Cherukuri AMK, Anne H, Chakilam R, Yadav D.   +6 more
europepmc   +1 more source

ANTIRHEUMATIC DRUGS IN PREGNANCY AND LACTATION [PDF]

Rheumatology, 1985
openaire   +3 more sources